GlassScriptPhysician profile
Dana Gamel
NPI 1457836330
$957.94
in general payments reported to CMS, 2019-2025
15 companies · $958 in 2025
The $958 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $201.21 | 2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $144.36 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.05 | 2025 | |
| Pfizer INC. | $115.40 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.26 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $66.98 | 2025 | Airsupra |
| Merck Sharp & Dohme LLC | $50.32 | 2025 | Lagevrio, Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $31.92 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $28.63 | 2025 | Gemtesa |
| Siemens Medical Solutions USA, INC. | $24.06 | 2025 | Immulite 1000 Immunoassay System |
| Xeris Pharmaceuticals, INC. | $23.10 | 2025 | Recorlev |
| Inspire Medical Systems, INC. | $20.72 | 2025 | Inspire |
| Averitas Pharma INC. | $17.52 | 2025 | Qutenza |
| Lundbeck LLC | $16.16 | 2025 | Rexulti |
| Shield Therapeutics INC | $14.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Gamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.